Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Sort by: Newest first Oldest first A-Z Z-A

  • A visual history of HIV survival in the UK

    A history of HIV survival in the UK Subscription

    Treatment for HIV has radically improved since the beginning of the epidemic in 1981. HIV-infected people in the UK are now surviving for decades, rather than months or years.

  • Red blood cells

    A move from HIV to haemato-oncology Subscription

    Specialist haemato-oncology pharmacist Elizabeth Davies describes how an interest in HIV pharmacy early in her career progressed to haemato-oncology and independent prescribing There may appear to be little common ground between the roles of specialist HIV pharmacist and haemato-oncology specialist, but that flies in the face of reality.

  • Joep Lange

    A pioneer in AIDS research from the very start Subscription

    Dutch researcher Joep Lange dedicated his career to groundbreaking HIV and AIDS research and was passionate about improving access to antiretroviral therapy in developing countries.

  • A view from the PJ letters archive

    By Ranveer Bassey

    I recently stumbled across the PJ archive and promptly got lostsomewhere in a 1999 version of pharmacy as depicted by readers' letters.

  • Aids ‘family tree’ traced back to Kinshasa

    New research has traced the origin of the Aids pandemic back to 1920s Kinshasha, where a “perfect storm” of rapid population growth, a roaring sex trade, and good railway transport facilitated the spread of the HIV virus.

  • Breast milk and HIV

    By Glow-worm

    Healthcare agencies are keen to maintain the nutritional and immunological benefits of breastfeeding in developing countries, even in infants whose mothers are HIV positive. Infant retroviral drug prophylaxis can reduce the rate of infection, but other issues such as cost, toxicity and drug resistance can limit its effectiveness.

  • Consider raltegravir as alternative to efavirenz for initial HIV therapy Subscription

    Raltegravir should be regarded as an alternative to efavirenz as part of a first-line combination regimen with tenofovir and emtricitabine in treatment-naive patients with HIV, the authors of a study published online in The Lancet yesterday (3 August 2009) suggest.

  • Contraindications for Eviplera Subscription

    Additions have been made to the list of mutations that exclude patients with HIV from treatment with Eviplera (emtricitabine/rilpivirine/tenofovir; Gilead). These are the tenofovir resistance-associated substitution K70E, and the combination of L100I+K103N as a rilpivirine resistance-associated substitution.

  • Daklinza for HIV co-infected patients Subscription

    The summary of product characteristics of Daklinza (daclatasvir; Bristol-Myers Squibb) has been updated to reflect the results of a study, which found the medicine is effective at treating hepatitis C when patients are also infected with HIV. This includes changes to the posology and information on interactions with other medicines. 

  • Daklinza licence extension Subscription

    Daklinza (daclatasvir; Bristol Myers Squibb), used in combination with other drugs to treat hepatitis C, has been approved for extended use for patients co-infected with HIV and also post liver transplantation by the European Medicines Agency. 

Show  10 per page20 per page50 per page

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.